Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia. The company's lead asset is ATL1102, an antisense oligonucleotide inhibitor of CD49d, which is in Phase IIb clinical trial for the treatment of Duchenne muscular dystrophy, multiple sclerosis, asthma, and other inflammatory indications. It also develops HMBD-002, a recombinant humanised monoclonal IgG4 antibody, which completed Phase I clinical tria...
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 61 3 9827 8999
Fax: 61 3 9859 7701
Address:
Collins Place, Level 30 35 Collins Street, Melbourne, Australia
